Silver

Silver

SCHEMBL6115455

O=S(=O)([O-])c1ccc(F)cc1F.[Ag+]

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

folP

The experimentally established mechanism targets of Silver. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.45
POLB P06746 1/20 0.41
ATM Q13315 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CCR2 P41597 3/20 0.41
PKM P14618 2/20 0.40
PKLR P30613 1/20 0.40
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
SOS1 Q07889 1/20 0.39
ALDH1A1 P00352 2/20 0.38
MAPT P10636 1/20 0.37
KCNH2 Q12809 2/20 0.36
PIK3CB P42338 1/20 0.36
PPME1 Q9Y570 1/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16341204 0.96 AKR1B1 (0.45) AKR1B1POLBATMTDP1CCR2
Potassium Ion SCHEMBL16341238 0.96 AKR1B1 (0.45) AKR1B1POLBATMTDP1CCR2
SCHEMBL2537983 0.82 HTR2A (0.38) AKR1B1POLBCCR2PKMPKLR
SCHEMBL548574 0.82 HTR2A (0.38) AKR1B1POLBCCR2PKMPKLR
SCHEMBL30113133 0.82 HTR2A (0.38) AKR1B1POLBCCR2PKMPKLR
Toliodium SCHEMBL5403487 0.80 MAPT (0.38) AKR1B1POLBCCR2ALDH1A1MAPT
SCHEMBL2964608 0.80 MAPT (0.36) AKR1B1POLBCCR2ALDH1A1MAPT
SCHEMBL778076 0.79 AKR1B1 (0.58) AKR1B1POLBATMTDP1CCR2
SCHEMBL3935273 0.78 PKM (0.50) POLBATMTDP1PKMPKLR
SCHEMBL4859182 0.78 LMNA (0.40) AKR1B1POLBTDP1CCR2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2821395-B1 Novel disulfonic acid ester as an additive for an electrolyte for a lithium secondary battery WAKO PURE CHEM IND LTD (JP) 2017-06-21 EP disclosed
EP-2821395-A2 Novel disulfonic acid ester as an additive for an electrolyte for a lithium secondary battery Wako Pure Chemical Industries, Ltd. (JP) 2015-01-07 EP disclosed
US-8716513-B2 Process for production of bis-quaternary ammonium salt, and novel intermediate WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2014-05-06 US disclosed
EP-2463266-A1 PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE Wako Pure Chemical Industries, Ltd. (JP) 2012-06-13 EP disclosed
US-20120130107-A1 PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120130107-A1 PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE ASS1, C1S, FHIT AKR1B1 674/4885POLB 3746/4885ATM 2248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.